Snyder H W, Seawell B W, Cochran S K, Balint J P, Jones F R
IMRE Corporation, Seattle, WA 98109.
J Clin Apher. 1992;7(3):110-8. doi: 10.1002/jca.2920070303.
A relationship is described between the interaction of circulating immune complexes (CIC) from plasma with staphylococcal protein A immunoadsorption treatment columns and modulation of antibody responses related to the specific CIC. Eluates from the initial immunoadsorption columns used to treat a series of patients with breast adenocarcinoma, cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (C-TTP/HUS), or immune thrombocytopenic purpura (ITP) were evaluated for disease-specific CIC containing Lex glycosphingolipid (Lex gl) adenocarcinoma-associated antigens or platelet autoantibody (anti-GPIIb/IIIa), together with the corresponding neutralizing antibody [anti-F(ab')2], and for nonspecific CIC containing cytomegalovirus (CMV) or herpes simplex virus type 1 (HSV-1) antigens. In addition, the levels of antibodies directed against CMV, HSV-1, Lex gl, and GPIIb/IIIa antigens, as well as anti-F(ab')2 antibodies, were compared in pretreatment and posttreatment serum samples. Columns used to treat breast adenocarcinoma patients contained only Lex gl CIC, and the only immunologic change observed after treatment was significant increases in anti-Lex gl antibodies in some patients. Columns used to treat C-TTP/HUS patients contained anti-GPIIb/IIIa-anti-F(ab')2 CIC, in addition to Lex gl CIC. After treatment, significant increases in anti-Lex gl and anti-F(ab')2 antibodies and significant decreases in anti-GPIIb/IIIa antibodies were observed in some patients. Columns used to treat ITP patients only exhibited anti-GPIIb/IIIa-anti-F(ab')2 CIC, and after treatment only decreases in anti-GPIIb/IIIa and increases in anti-F(ab')2 antibodies were observed in some patients.(ABSTRACT TRUNCATED AT 250 WORDS)
本文描述了血浆中循环免疫复合物(CIC)与葡萄球菌蛋白A免疫吸附治疗柱的相互作用,以及与特定CIC相关的抗体反应调节之间的关系。对用于治疗一系列乳腺癌、癌症化疗相关血栓性血小板减少性紫癜/溶血尿毒综合征(C-TTP/HUS)或免疫性血小板减少性紫癜(ITP)患者的初始免疫吸附柱洗脱液进行评估,检测其中含Lex神经节苷脂(Lex gl)腺癌相关抗原或血小板自身抗体(抗GPIIb/IIIa)的疾病特异性CIC,以及相应的中和抗体[抗F(ab')2],同时检测含巨细胞病毒(CMV)或单纯疱疹病毒1型(HSV-1)抗原的非特异性CIC。此外,比较了治疗前和治疗后血清样本中针对CMV、HSV-1、Lex gl和GPIIb/IIIa抗原的抗体水平以及抗F(ab')2抗体水平。用于治疗乳腺癌患者的柱中仅含Lex gl CIC,治疗后观察到的唯一免疫学变化是部分患者抗Lex gl抗体显著增加。用于治疗C-TTP/HUS患者的柱中除Lex gl CIC外,还含抗GPIIb/IIIa -抗F(ab')2 CIC。治疗后,部分患者抗Lex gl和抗F(ab')2抗体显著增加,抗GPIIb/IIIa抗体显著减少。用于治疗ITP患者的柱仅显示抗GPIIb/IIIa -抗F(ab')2 CIC,治疗后部分患者仅出现抗GPIIb/IIIa抗体减少和抗F(ab')2抗体增加。(摘要截选至250字)